MabCure Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MBCI research report →
About the company
MabCure Inc. , a development stage company, engages in developing and commercializing its proprietary antibody technology for the early detection of cancer, and for the creation of specific therapeutics against cancer. It owns a proprietary technology for the generation of monoclonal antibodies against desired antigens, such as cancer markers.
- CEO
- Jehu Hand
- IPO
- 2007
- Employees
- 3
- HQ
- White Plains, NY, US
Price Chart
- Market Cap
- $21.96K
- P/E
- -0.00
- P/S
- 0.04
- P/B
- 0.00
- EV/EBITDA
- -0.01
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -141.95%
- Net Margin
- -2490.30%
- ROE
- -127.05%
- ROIC
- -17.16%
- Revenue
- $500.00K · 0.00%
- Net Income
- $-12,451,496 · -769.12%
- EPS
- $-0.20 · -765.80%
- Op Income
- $-709,745
- FCF YoY
- 91.12%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 7.55
- Avg Volume
- 936
Get TickerSpark's AI analysis on MBCI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 19, 11 | Berdugo Gad | other | 200,000 |
| Sep 24, 11 | Berdugo Gad | other | 120,000 |
| Jul 7, 08 | KATZ STEVEN | other | 0 |
Our MBCI coverage
Recent articles, reports, and earnings notes.
No research on MBCI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MBCI report →Similar companies
Peers in the same neighborhood.